MOTS-c, Exercise and AMPK: Folate-Cycle, Nuclear-Translocation and Muscle Signalling Research

RESEARCH · MOTS-c · EXERCISE & AMPK

MOTS-c, Exercise and AMPK: Folate-Cycle, Nuclear-Translocation and Muscle Signalling Research

MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S rRNA [1]. Our earlier articles cover its discovery and the overall research picture and circulating human levels and assay limits. This article stays with mechanism: how cell and mouse studies connect MOTS-c to AMPK, to the nucleus and to exercise adaptation in skeletal muscle. PurixLab’s MOTS-c 10mg is a research material for laboratory research use only.

From the folate cycle to AMPK

The founding study reported that the primary target organ of MOTS-c appears to be skeletal muscle, and that its cellular actions inhibit the folate cycle and the tethered de novo purine biosynthesis pathway, leading to AMPK activation [1]. Later papers describe the intermediate step as accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous AMPK activator [2]. A note on terminology: MOTS-c is sometimes linked to the folate receptor FOLR1, but in a PubMed search in October 2026 we found no study reporting such an interaction. The published mechanism concerns intracellular folate-cycle metabolism, not the folate receptor [1,2].

A mitochondrial peptide in the nucleus

Kim and colleagues showed that MOTS-c translocates to the nucleus following metabolic stress in an AMPK-dependent manner. In the nucleus it regulated a broad range of genes in response to glucose restriction, including genes with antioxidant response elements (AREs), and interacted with ARE-regulating stress-responsive transcription factors such as NFE2L2/NRF2 [3]. That work underpins the description of MOTS-c as a mitochondrial-encoded regulator of nuclear gene expression. A 2025 rat and cell study proposed one transport route: under hypoxia-reoxygenation, ROS-dependent phosphorylation of MYH9 at Ser1943 by CK2A enabled MOTS-c binding to MYH9-γ-actin complexes for nuclear transport, and RNA-seq with ChIP-seq indicated direct MOTS-c interaction with promoters of ARE-containing antioxidant genes such as HMOX1 and NQO1 [4].

Exercise as a trigger

Reynolds and colleagues reported that MOTS-c enhanced physical performance in young (2 months), middle-aged (12 months) and old (22 months) mice, regulated nuclear genes related to metabolism and proteostasis, and supported myoblast adaptation to metabolic stress. Intermittent treatment initiated late in life, at 23.5 months, increased physical capacity, and in humans exercise induced endogenous MOTS-c expression in skeletal muscle and in circulation [5]. In rodents, 4-8 weeks of voluntary running increased MOTS-c protein about 1.5- to 5-fold in several hindlimb muscles, sustained through 4-6 weeks of detraining and coinciding with more mtDNA. Nuclear translocation was seen in two of six soleus muscles 1 h after downhill running, but not in plantaris from the same animals [6].

The relationship may run both ways. In C2C12 myotubes, the AMPK inhibitor Compound C reduced PGC-1α and MOTS-c expression and PGC-1α knockdown reduced MOTS-c, while treadmill training in obese mice raised MOTS-c, PGC-1α and GLUT4 together with AMPK and ACC phosphorylation, suggesting that the AMPK/PGC-1α pathway also regulates MOTS-c production [2]. A study of endurance-trained mice linked better skeletal muscle mitochondrial respiration to MOTS-c secretion and AMPK/PGC-1α activation [7].

Bioenergetics: PGC-1α and AMPK both required

A 2026 study in two transgenic mouse strains reported that MOTS-c augmented muscle mitochondrial bioenergetic performance in a manner reliant on both PGC-1α and AMPK, apparently without changing mitochondrial respiratory protein content, and lowered mitochondrial ROS emission; RNA sequencing pointed to subtle effects on redox handling, mitochondrial integrity and OXPHOS efficiency [8]. The same paper found increased interstitial MOTS-c but no arterio-venous difference across exercising human muscle, suggesting that skeletal muscle may not be the source of circulating MOTS-c during exercise [8]. That complicates a simple exercise-released-myokine picture.

Beyond AMPK: CK2, AKT and myostatin

AMPK is not the only proposed target. Kumagai and colleagues found that MOTS-c prevented palmitic-acid-induced atrophy in C2C12 myotubes and lowered plasma myostatin in diet-induced obese mice, acting through a CK2-PTEN-mTORC2-AKT-FOXO1 chain [9]. A 2024 study then reported that MOTS-c binds CK2 directly and activates it in cell-free systems, that suppressing CK2 activity blunted MOTS-c effects on muscle atrophy and glucose uptake, and that MOTS-c stimulated CK2 in muscle while suppressing it in fat [10]. In a casting model, immobilisation reduced muscle mass by about 15%, compared with about 5% in MOTS-c-treated mice, with normalised AKT/FOXO signalling and RNA-seq changes in PPAR-pathway adipogenesis genes [11].

The K14Q variant as a natural experiment

An East Asian-specific mtDNA variant, m.1382A>C, changes the 14th amino acid of MOTS-c (K14Q) and yields a less active peptide. In a meta-analysis of three cohorts (n = 27,527), men but not women with the C allele had a higher prevalence of type 2 diabetes, and in one cohort the excess appeared only in the least physically active tertile; K14Q-MOTS-c did not reproduce the weight and glucose-tolerance effects of the native peptide in high-fat-fed male mice [12]. The variant was also associated with a higher proportion of fast-twitch MHC-IIx fibre and higher leg peak torque in men, and its allele frequency was 6.5% in sprint/power athletes, 5.1% in controls and 2.9% in endurance athletes [13]. K14Q MOTS-c also showed reduced binding to CK2 [10].

What remains open

  • Mouse-to-human gap. Mechanistic data come mostly from cultured cells and mice; human exercise data are limited and partly conflicting [14].
  • Overlapping pathways. Variant and combination studies suggest exercise and MOTS-c act through distinct and overlapping pathways [14].
  • Source during exercise. Muscle may not be the source of circulating MOTS-c [8].
  • Several targets. AMPK, CK2 and nuclear transcription factors have each been proposed, and how they fit together is unresolved [3,10].

MOTS-c 10mg at PurixLab

MOTS-C 10mg: a labelled lyophilized research vial with 10mg per vial, C$54 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/mots-c-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View MOTS-c 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. PubMed 25738459 · PMC4350682 · doi:10.1016/j.cmet.2015.02.009
  2. Yang B, Yu Q, Chang B, et al. MOTS-c interacts synergistically with exercise intervention to regulate PGC-1α expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway. Biochim Biophys Acta Mol Basis Dis. 2021;1867(6):166126. PubMed 33722744 · doi:10.1016/j.bbadis.2021.166126
  3. Kim KH, Son JM, Benayoun BA, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524.e7. PubMed 29983246 · PMC6185997 · doi:10.1016/j.cmet.2018.06.008
  4. Li X, Zhan F, Qiu G, et al. MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes. Redox Biol. 2025;84:103681. PubMed 40403491 · PMC12150175 · doi:10.1016/j.redox.2025.103681
  5. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PubMed 33473109 · PMC7817689 · doi:10.1038/s41467-020-20790-0
  6. Hyatt JK. MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose. Physiol Rep. 2022;10(13):e15377. PubMed 35808870 · PMC9270643 · doi:10.14814/phy2.15377
  7. Feng Y, Rao Z, Tian X, et al. Endurance training enhances skeletal muscle mitochondrial respiration by promoting MOTS-c secretion. Free Radic Biol Med. 2025;227:619-628. PubMed 39706498 · doi:10.1016/j.freeradbiomed.2024.12.038
  8. Gudiksen A, Hansen CC, van der Stede T, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free Radic Biol Med. 2026;246:682-696. PubMed 41520850 · doi:10.1016/j.freeradbiomed.2026.01.002
  9. Kumagai H, Coelho AR, Wan J, et al. MOTS-c reduces myostatin and muscle atrophy signaling. Am J Physiol Endocrinol Metab. 2021;320(4):E680-E690. PubMed 33554779 · PMC8238132 · doi:10.1152/ajpendo.00275.2020
  10. Kumagai H, Kim SJ, Miller B, et al. MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience. 2024;27(11):111212. PubMed 39559755 · PMC11570452 · doi:10.1016/j.isci.2024.111212
  11. Kumagai H, Kim SJ, Miller B, et al. Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration. Am J Physiol Endocrinol Metab. 2024;326(3):E207-E214. PubMed 38170165 · PMC11196098 · doi:10.1152/ajpendo.00285.2023
  12. Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021;13(2):1692-1717. PubMed 33468709 · PMC7880332 · doi:10.18632/aging.202529
  13. Kumagai H, Natsume T, Kim SJ, et al. The MOTS-c K14Q polymorphism in the mtDNA is associated with muscle fiber composition and muscular performance. Biochim Biophys Acta Gen Subj. 2022;1866(2):130048. PubMed 34728329 · PMC8741734 · doi:10.1016/j.bbagen.2021.130048
  14. Woodhead JST, Merry TL. Mitochondrial-derived peptides and exercise. Biochim Biophys Acta Gen Subj. 2021;1865(12):130011. PubMed 34520826 · doi:10.1016/j.bbagen.2021.130011

Leave a Comment

Your email address will not be published. Required fields are marked *